A joint event: IV Annual IMPPC Conference/1st ICO-IDIBELL Hereditary Cancer Program Meeting

Hereditary and Familial Cancer In The Personal Genomics Era

CosmoCaixa, Barcelona 14-15 March 2013

Coordinator of the Molecular Diagnostics Units of the Hereditary Cancer
Program at the Catalan Institute of Oncology (ICO-IDIBELL)

Conxi Lázaro studied biology in the University of Barcelona. Her PhD thesis was completed in the Department of Genetics at the Institut de Recerca Oncològica (IRO) under the supervision of Dr. Estivill. She worked as a Molecular Geneticist at the Genetics Service of Hospital Clínic and after that she returned to IRO to lead the Neurofibromatosis 1 group as well as to participate in several research projects related to common multifactorial disorders (asthma and psoriasis). During 2003/04 she was a visiting scientist in the Cancer Center of the Massachussetts General Hospital (Harvard, Boston). In 2006 she started work in her current position as a director of the Molecular Diagnostics Unit at ICO. In addition to the routine clinical work, Dr. Lázaro leads two research lines, one focussing on deciphering the genetic basis underlying the Hereditary Breast and Ovarian Cancer Syndrome, and another mainly focussing on the development of new therapeutical strategies for Neurofibroamtosis Type 1. Currently she is also involved in several projects aimed to use Next Generation Sequencing (NGS) for genetic testing purposes.

5 selected papers:

Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families.
Fernández-Rodríguez J, Quiles F, Blanco I, Teulé A, Feliubadaló L, Valle JD, Salinas M, Izquierdo A, Darder E, Schindler D, Capellá G, Brunet J, Lázaro C*, Pujana MA*
BMC Cancer. 2012 Mar 8;12:84. doi: 10.1186/1471-2407-12-84.

Identification of a new complex rearrangement affecting exon 20 of BRCA1.
Del Valle J, Campos O, Velasco A, Darder E, Menéndez M, Feliubadaló L, Tornero E, Blanco I, Izquierdo A, Brunet J, Capellá G, Lázaro C.
Breast Cancer Res Treat. 2011 Nov;130(1):341-4. Epub 2011 Jul 15.

Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.
Menéndez M, Castellsagué J, Mirete M, Pros E, Feliubadaló L, Osorio A, Calaf M, Tornero E, del Valle J, Fernández-Rodríguez J, Quiles F, Salinas M, Velasco A, Teulé A, Brunet J, Blanco I, Capellá G, Lázaro C.
Breast Cancer Res Treat. 2012 Apr;132(3):979-92. Epub 2011 Jul 7.

A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1-splice mutation and the presence of a complex mosaicism.
Fernández-Rodríguez J, Castellsagué J, Benito L, Benavente Y, Capellá G, Blanco I, Serra E, Lázaro C.
Hum Mutat. 2011 Jul;32(7):705-9. doi: 10.1002/humu.21500. Epub 2011 Jun 2.

Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
Pros E, Fernández-Rodríguez J, Canet B, Benito L, Sánchez A, Benavides A, Ramos FJ, López-Ariztegui MA, Capellá G, Blanco I, Serra E, Lázaro C.
Hum Mutat. 2009 Mar;30(3):454-62.

Link to the Hereditary Cancer Program at the ICO